Memo Therapeutics AG
Memo Therapeutics AG is a Healthcare & Life Sciences startup based in Switzerland, since acquired, 8 tracked investors.
About Memo Therapeutics AG
Memo Therapeutics AG is a company headquartered in Switzerland. Memo Therapeutics AG has been acquired. Brouky classifies it under Healthcare & Life Sciences. Brouky records 8 investors associated with the company.
Memo Therapeutics AG is a biotech company developing therapeutic antibodies derived from human immune responses; its lead program potravitug is in Phase II for treating BK polyomavirus infection in kidney transplant recipients. The company also uses its proprietary DROPZYLLA technology to mine antibody repertoires for additional antiviral and oncology antibody candidates.
Explore Memo Therapeutics AG's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.